Revance Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Revance Therapeutics

01/03/2023 03:29

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 95 cents​​ per share for the quarter ended in December.
The mean expectation of twelve analysts for the quarter was
for a loss of 95 cents per share.
    * Revenue rose 92.4% to $49.92 million from a year ago;
analysts
expected $46.55 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.82​.
    * The mean earnings estimate of analysts had risen by
about 15.4%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Revance Therapeutics Inc shares had risen by 90.1% this
quarter.
    * The company reported a quarterly loss of $145.95 million.
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $35.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 03:29 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.95          -0.95          Met
 Sep. 30 2022      -0.89          -1.17          Missed
 Jun. 30 2022      -0.86          -0.88          Missed
 Mar. 31 2022      -0.83          -0.94          Missed